ICI/TKI Combo Maintains Survival Benefit in Advanced RCC

(MedPage Today) -- SAN FRANCISCO -- First-line nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to demonstrate clinically meaningful survival benefits in advanced renal cell carcinoma (RCC). An update of the CheckMate 9ER trial, which...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news